Evidence map›Paper›PMID 39179741›Full record

ReviewEMBO molecular medicine2024

Human breast tissue engineering in health and disease.

Maj-Britt Buchholz, Demi I Scheerman, Riccardo Levato, Ellen J Wehrens, Anne C Rios

Abstract readReview
In one paragraph

Review in EMBO molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maj-Britt BuchholzPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Demi I ScheermanDepartment of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.ORCID 0009-0001-0976-4512
Riccardo Levato *Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Ellen J Wehrens *Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Anne C Rios *Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. a.c.rios@prinsesmaximacentrum.nl.ORCID 0000-0002-9082-8068

Funding

EC | ERC | HORIZON EUROPE European Research Council (ERC) 949806
6 · The paper itself

Abstract

The human mammary gland represents a highly organized and dynamic tissue, uniquely characterized by postnatal developmental cycles. During pregnancy and lactation, it undergoes extensive hormone-stimulated architectural remodeling, culminating in the formation of specialized structures for milk production to nourish offspring. Moreover, it carries significant health implications, due to the high prevalence of breast cancer. Therefore, gaining insight into the unique biology of the mammary gland can have implications for managing breast cancer and promoting the well-being of both women and infants. Tissue engineering techniques hold promise to narrow the translational gap between existing breast models and clinical outcomes. Here, we provide an overview of the current landscape of breast tissue engineering, outline key requirements, and the challenges to overcome for achieving more predictive human breast models. We propose methods to validate breast function and highlight preclinical applications for improved understanding and targeting of breast cancer. Beyond mammary gland physiology, representative human breast models can offer new insight into stem cell biology and developmental processes that could extend to other organs and clinical contexts.

Indexed as

Breast NeoplasmsTissue EngineeringAnimalsBreastFemaleHumansMammary Glands, HumanPregnancyBioprintingHuman breast modelingMammary gland biologyOrgan-on-a-chipTissue engineering

Identifiers

PMID39179741
PMCPMC11473723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.